绝对中性粒细胞计数与头颈癌根治性放化疗患者结局的关联
本研究为观察性队列研究,纳入2007年6月至2023年4月接受根治性放化疗的非转移性头颈癌患者668例,分析绝对中性粒细胞计数(ANC)作为连续变量与预后的关联。中位随访30.3个月, elevated ANC与更差的总生存(aHR 1.02,95%CI 1.01-1.04,p=0.003)、无进展生存(aHR 1.03,95%CI 1.01-1.04,p<0.001)和远处失败(aHR 1.03,95%CI 1.01-1.05,p=0.007)相关,但与局部区域失败无关(aHR 1.02,95%CI 1.00-1.05,p=0.10)。在p16阳性肿瘤患者中,高ANC与更差的OS、PFS、LRF和DF相关。结论提示 elevated ANC是独立的不良预后因素。
要点
- elevated ANC与头颈癌根治性放化疗患者更差的OS、PFS和远处失败独立相关。
- ANC与局部区域失败无关,但在p16阳性肿瘤患者中高ANC与更差LRF相关。
- ANC可作为头颈癌根治性放化疗的预后生物标志物。
核心结论
- elevated ANC是头颈癌根治性放化疗患者更差生存和远处转移结局的独立不良预后因素。
- 在p16阳性肿瘤患者中,高ANC还与更差的局部区域失败相关。
研究设计与样本
- 观察性队列研究,查询机构数据库纳入2007年6月至2023年4月接受根治性放化疗的非转移性头颈癌患者668例。
- ANC作为连续变量分析,采用Cox多变量分析、Fine-Gray多变量分析和倾向性评分匹配(以中位值为截断值)。
- 在p16阳性队列(344例)中进行亚组分析。
主要发现
- 中位随访30.3个月(四分位距9.9-60.7)。
- elevated ANC与更差OS(aHR 1.02,95%CI 1.01-1.04,p=0.003)、PFS(aHR 1.03,95%CI 1.01-1.04,p<0.001)和DF(aHR 1.03,95%CI 1.01-1.05,p=0.007)相关,但与LRF无关(aHR 1.02,95%CI 1.00-1.05,p=0.10)。
- 在278对匹配患者中观察到相似结果。
- 在344例p16阳性肿瘤患者中,高ANC与更差OS(aHR 1.03,95%CI 1.00-1.06,p=0.046)、PFS(aHR 1.05,95%CI 1.02-1.07,p<0.001)、LRF(aHR 1.08,95%CI 1.05-1.12,p<0.001)和DF(aHR 1.04,95%CI 1.01-1.08,p=0.02)相关。
临床怎么用
- ANC可作为头颈癌根治性放化疗患者的预后评估指标,高ANC提示更差生存和远处转移风险。
- 在p16阳性患者中,高ANC还提示局部区域失败风险增加,可能有助于风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Systematic inflammation plays an integral role in tumor development and metastasis. High neutrophil counts, among various peripheral blood biomarkers, have been shown to be associated with worse outcomes in multiple cancer types. To evaluate the absolute neutrophil count (ANC) as a prognostic biomarker in head and neck cancer, we performed an observational cohort study of patients undergoing definitive chemoradiation. METHODS: Our institutional database was queried for patients with non-metastatic head and neck cancer who underwent definitive chemoradiation between June 2007 and April 2023. ANC was analyzed as a continuous variable. Cox multivariable analysis (MVA), Fine-Gray MVA, and propensity score matching with its median value as a cutoff were performed. Subgroup analyses were performed among p16-positive cohorts. RESULTS: A total of 668 patients who met our criteria. Median follow up was 30.3 months (interquartile range 9.9-60.7). Elevated ANC as a continuous variable was associated with worse overall survival (OS; adjusted hazards ratio [aHR] 1.02, 95% confidence interval [CI] 1.01-1.04, p = 0.003), progression free survival (PFS; aHR 1.03, 95% CI 1.01-1.04, p < 0.001), and distant failure (DF; aHR 1.03, 95% CI 1.01-1.05, p = 0.007), but not locoregional failure (LRF; aHR 1.02, 95% CI 1.00-1.05, p = 0.10). Similar findings were noted among 278 matched pairs. Among 344 patients with p16-positive tumors, high ANC was associated with worse OS (aHR 1.03, 95% CI 1.00-1.06, p = 0.046), PFS (aHR 1.05, 95% CI 1.02-1.07, p < 0.001), LRF (aHR 1.08, 95% CI 1.05-1.12, p < 0.001), and DF (aHR 1.04, 95% CI 1.01-1.08, p = 0.02). CONCLUSIONS: Our study suggested that elevated ANC was an independent, adverse prognostic factor for worse survival and distant metastasis outcomes. It was also associated with worse locoregional failure among patients with p16-positive tumors.
引用
- Gill J, Virk J, Azam M, et al. Association of Absolute Neutrophil Count With Outcomes in Patients With Head and Neck Cancer Receiving Definitive Chemoradiation. Head Neck. 2026. PMID: 42175580. doi:10.1002/hed.70324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。